This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Pain	Transient receptor potential vanilloid 1 (TRPV1; VR1)	<p><i>In vitro</i> studies identified a class of TRPV1 antagonists that could help treat pain. A cell-based electrophysiological pain assay identified a lead triazine analog that antagonized TRPV1 with an IC₅₀ of 50 nM. Future studies could include testing the lead compound in animal models of pain.</p> <p>XEN-D0501, a TRPV1 antagonist from Provesica Ltd., is in Phase II testing to treat overactive bladder (OAB).</p> <p>705498, a topical TRPV1 antagonist from GlaxoSmithKline plc, is in Phase I testing to treat dermal itch.</p> <p>GRC 6211, a TRPV1 antagonist from Glenmark Pharmaceuticals Ltd., is in Phase I testing to treat incontinence and pain.</p> <p>SciBX 4(41); doi:10.1038/scibx.2011.1151 Published online Oct. 20, 2011</p>	Patent and licensing status unavailable	<p>Vidal-Mosquera, M. <i>et al. J. Med. Chem.</i>; published online Sept. 27, 2011; doi:10.1021/jm200981s</p> <p>Contact: Angel Messeguer, Institute of Advanced Chemistry of Catalonia, Barcelona, Spain e-mail: angel.messeguer@iqac.csic.es</p>